Alexander Maxwell

Alexander Maxwell

AMax101

I am currently a student at the George Washington University majoring in Finance and Business Economics and Public Policy. My investing philosophy: Biotechs, Biotechs, and more biotechs. Biotech is my favorite sector to write about and my favorite sector to invest in.

Recent articles

Will FDA Labelling Be MannKind's Downfall?

While FDA approval may have come wrapped in a pretty box for shareholders, what is inside the box in terms of FDA warnings could be a huge problem for MannKind and Afrezza.


Is There Any Hope for Dendreon?

With large debt and a history of net losses, is it too little too late to turn around Dendreon?




3 Stocks with FDA Catalysts Incoming

For many companies, FDA decisions represent the hallmark of years of investment. Due to the amount of time and money that was spent developing these drugs, they can also represent significant catalysts for investors.



The Changing Landscape in Chronic Diabetic Foot Ulcers

After the release of phase 3 data, Osiris Pharmaceuticals has just changed the dynamics of the chronic diabetic foot ulcer market. Other companies will, of course, be affected by Osiris' clinical data.